ArticleFrontiers in cellular and infection microbiology2021
A Novel Tigecycline Adjuvant ML-7 Reverses the Susceptibility of Tigecycline-Resistant
Article in Frontiers in cellular and infection microbiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 27 citations in OpenAlex.
- 3‑Methylthiopropionic Acid Kills Carbapenem-ResistantJACS Au · 2026Article
- SMAP29: an antibacterial peptide that possesses anti-inflammatory and fast bactericidal actions against colistin-resistant gram-negative bacteria.Microbiology spectrum · 2026Article
- Ceftazidime-avibactam drives mutations, insertion, or overexpression in blaScientific reports · 2026Article
- Within-host mechanisms of resistance evolution in polymyxin B-resistant Klebsiella pneumoniae without prior exposure.Annals of clinical microbiology and antimicrobials · 2026Article
- Inosine monophosphate overcomes the coexisting resistance of mcr-1 and blaJournal of advanced research · 2026Article
- α-Terpineol reversesFrontiers in cellular and infection microbiology · 2026Article
- Exposure to ceftazidime-avibactam induced antimicrobial resistance and enhanced virulence in aiScience · 2025Article
- Notoginsenoside Ft1 enhances the effectiveness of gentamicin against Escherichia coli by interfering with intrinsic antibacterial mechanisms.BMC microbiology · 2025Article
- Restoring colistin sensitivity in colistin-resistant gram-negative bacteria: combinatorial use of α-terpineol and colistin.Microbiology spectrum · 2025Article
- Article
- Antimicrobial and Anti-Efflux Machinery of FDA-Approved Proton Pump Inhibitors and Vitamins AgainstMicroorganisms · 2025Article
- Main Ingredient of Yinhua Pinggan Granules Combined with Meropenem Alleviated Lung Injury Induced by Multidrug-ResistantJournal of microbiology and biotechnology · 2025Article
- Emergence and dissemination of multidrug-resistantFrontiers in cellular and infection microbiology · 2025Article
- Dual-Mechanism Peptide SR25 has Broad Antimicrobial Activity and Potential Application for Healing Bacteria-infected Diabetic Wounds.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Repurposing harmaline as a novel approach to reverse tmexCD1-toprJ1-mediated tigecycline resistance against klebsiella pneumoniae infections.Microbial cell factories · 2024Article
- Bacterial Efflux Pump Inhibitors Reduce Antibiotic Resistance.Pharmaceutics · 2024Review
- A promising metabolite, 9-aminominocycline, restores the sensitivity of tigecycline againstFrontiers in microbiology · 2024Article
- Clonal transmission of polymyxin B-resistant hypervirulent Klebsiella pneumoniae isolates coharboring blaBMC microbiology · 2023Article
- Purine metabolism regulatesFrontiers in microbiology · 2023Article
- ML364 exerts the broad-spectrum antivirulence effect by interfering with the bacterial quorum sensing system.Frontiers in microbiology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The increasing incidence of tigecycline resistance undoubtedly constitutes a serious threat to global public health. The combination therapies had become the indispensable strategy against this threat. Herein, 11 clinical tigecycline-resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.